CRCD2, a first-in-class specific small molecule inhibitor of the cytosolic 5′ nucleotidase II (NT5C2), has been reported to be broadly active against NT5C2 in acute lymphoblastic leukemia (ALL) [57]. Here, NT5C2 is linked to acute lymphoblastic leukemia.